XCSport体育
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
XCSport体育:Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
XCSport体育:Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
XCSport体育:Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
XCSport体育:Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
XCSport体育:Company Profile
Corporate Culture
Honor
XCSport体育:Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
XCSport体育:Technology Platform
Quality Management
XCSport体育:Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
Highlights
Download
Media Reports
Media Enquiry
2020-12-31
First Patient Dosed in Phase 2 Study of Henlius Innovative Anti-PD-1 Monoclonal Antibody HLX10 for the Treatment of Chronic Hepatitis B
2020-12-13
First Patient Dosed in Phase 3 Clinical Trial of Anti-PD-1 mAb HLX10 in Combination with Bevacizumab Biosimilar HLX04 in Patients with Metastatic nsNSCLC
2020-12-13
First Patient Dosed in Phase 3 Study of Anti-PD-1 mAb in Combination with Chemotherapy in Neo-/Adjuvant Treatment for Patients with Gastric Cancer
2020-12-09
The Anti-PD-1 mAb Combined with Anti-EGFR mAb Therapy of Henlius Received Approvals to Conduct Clinical Trials by NMPA
2020-12-09
First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 DLBCL Study
2020-12-05
Henlius and FARMA DE COLOMBIA Enter into Exclusive License Agreement for Rituximab HLX01
2020-11-27
A Novel Anti-PD-1 Antibody HLX10 Study Led to the Initiation of Combination Immunotherapy
2020-11-27
A Novel Anti-EGFR Antibody HLX07 for Potential Treatment of Squamous Cell Carcinoma of the Head and Neck
2020-11-26
First China-Manufactured Trastuzumab Biosimilar HLX02 Global Phase 3 Trial Met Primary Endpoint in Breast Cancer
1
2
3
4